Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

37.86 +0.34 (+0.91%)
Official Closing Price Updated: 4:15 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
15 Analysts Have This To Say About Exelixis
 
Via Benzinga
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL is showing decent growth, but is still valued reasonably. 
Via Chartmill
(EXEL) - Analyzing Exelixis's Short Interest
 
Via Benzinga
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
From Exelixis, Inc.
Via Business Wire
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
 
Via Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive. 
Via Chartmill
Do Not Get Caught Holding Story Stocks- The Market Is Unforgiving
The stock market is already oversold, just not washed out yet. 
Via Talk Markets
Topics Stocks / Equities
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Exelixis, Inc.
Via Business Wire
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
As the calendar winds down, the stock market often heats up. This 
Via Talk Markets
Topics Stocks / Equities
Ten Young Ones
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays. 
Via Talk Markets
Topics Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.